Infectious Complications after Monoclonal Antibody Therapy in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
- Author:
Ji Man KANG
1
;
Young Bae CHOI
;
Eun Hye KONG
;
Soo Han CHOI
;
Hee Won CHUEH
;
Soo Hyun LEE
;
Ju Youn KIM
;
Eun Joo CHO
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hong Hoe KOO
;
Yae Jean KIM
Author Information
1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. yaejeankim@skku.edu
- Publication Type:Original Article
- Keywords:
Monoclonal antibody;
Infectious complications;
Allogeneic hematopoietic cell transplantation;
Children
- MeSH:
Cell Transplantation;
Child;
Humans;
Incidence;
Medical Records;
Retrospective Studies;
Transplants
- From:Clinical Pediatric Hematology-Oncology
2011;18(1):27-33
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: We evaluated characteristics of infectious complications in pediatric patients who received monoclonal antibody (mAb) therapy after allogeneic hematopoietic cell transplantation (HCT).METHODS: Between February 2004 and May 2009, 17 pediatric patients (<19 years at diagnosis) who received mAbs were identified as a study group (mAb group). One hundred twenty-two pediatric allogeneic HCT patients (<19 years at diagnosis) who did not receive mAb during the same period were identified as a control group (non-mAb group). A retrospective chart review of medical records was performed for the incidence of infectious complications and mortality.RESULTS: In the mAb group, 12 of the 17 patients (70.6%) had 29 infectious complications (1.71 episodes per person), whereas 89 of the 122 patients (73.8%) had 162 infectious complications (1.32 episodes per person) in the non-mAb group (P=0.838). Although, there were no significant differences in characteristics or incidence of infectious complications between the two groups, the infection-associated mortality rate was significantly higher in the mAb group compared to non-mAb group (29.4% vs. 8.2% P=0.021; RR 3.44, 95% CI, 1.407 to 8.433).CONCLUSION: The mAb therapy was associated with significantly high mortality in pediatric allogeneic HCT recipients.
